|
|
| Strategy, Innovation And The Future Of CDMOs | Q&A | PCI Pharma Services | Explore expert insights on the forces reshaping the CDMO landscape — from onshoring and capacity investment to patient-focused innovation — and what it takes to stay at the forefront. |
|
|
|
|
|
|
By Louis Garguilo, chief editor, Outsourced Pharma | Kodak – the company and Eastman Business Park in Rochester, NY. – was the focus of a recent editorial. But the man in front of Kodak’s attempted comeback is Jim Continenza, Chairman and CEO, is a topic unto himself. He is as animated as any public-company CEO you’ll encounter. And he knows his audience; early in his conversation with Chief Editor Louis Garguilo he says Kodak has always supplied CDMOs and the industry with important chemicals. Today he brings the industry an animated articulation of manufacturing suppliers. | |
|
|
Why Isolators Do Not Automatically Ensure Annex 1 Compliance | By Juergen M. Metzger, Pharma-Technology-Consulting, LLC | Isolators are powerful tools, but they do not automatically ensure compliance with EU GMP Annex 1. RABS are frequently dismissed too quickly. The difference is not the technology itself, but how it is applied. |
|
|
INDUSTRY INSIGHTS CONTINUED |
|
|
|
|
| Decoding ADC ADME With Tailored Strategies | Article | BioDuro | Overcome the complex ADME and DDI challenges of antibody–drug conjugates with tailored, data-driven strategies that accelerate development and support regulatory success. |
|
|
|
|
|
|
|
|
OUTSOURCED PHARMA CAPABILITIES UPDATE |
|
|
|
CDMOs in biologics, cell and gene, and small molecule share their capabilities and available capabilities. See for yourself why this virtual event has become a wildly popular resource to identify options for your development and manufacturing needs. |
|
|
| Connect With Outsourced Pharma: |
|
|
|
